Visual Abstract
Tirzepatide (TZP), a dual GIP/GLP-1 receptor agonist (RA) for type 2 diabetes (T2D), has shown clinically meaningful glycemic control improvements and bodyweight (BW) loss in patients with T2D inadequately controlled with diet and exercise alone. We evaluated the effect of TZP treatment vs. placebo (PBO) in patient-reported outcomes (PROs) measuring health status, self-perceptions impacted by BW, and ability to perform activities of daily living. Patients were randomized (1:1:1:1) to once weekly TZP 5, 10, 15 mg, and PBO. PRO measures assessed at baseline and week 40 were: EQ-5D-5L, Impact of Weight on Self-Perceptions Questionnaire (IW-SP), and Ability to Perform Physical Activities of Daily Living (APPADL). Higher PRO scores indicate better outcomes. Scores for all PRO measures improved significantly from baseline at 40 week for all TZP doses (p<0.05) and only IW-SP for PBO. TZP 10 mg and 15 mg groups significantly improved in EQ VAS and IW-SP scores at week 40 vs. PBO (p<0.05). There were no statistically significant differences between the TZP doses and placebo in EQ-5D-5L index and APPADL scores. Improvements in EQ VAS and IW-SP scores indicate that patients’ overall assessment of their health and BW-related self-perception improved with TZP compared with PBO. These PROs may help clinicians understand patient perspectives regarding their quality of life after starting tirzepatide treatment.
K. Boye: Employee; Self; Eli Lilly and Company, Employee; Spouse/Partner; Eli Lilly and Company. M. Yu: Employee; Self; Lilly Diabetes, Employee; Spouse/Partner; LifeLabs, Stock/Shareholder; Self; Lilly Diabetes, Stock/Shareholder; Spouse/Partner; Lilly Diabetes. C. Lee: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. H. Mao: Employee; Self; Eli Lilly and Company. X. Cui: Employee; Self; Eli Lilly and Company. L. Fernandez lando: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. V. Thieu: None.
Eli Lilly and Company
